News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Speeds Review of Bayer AG (BAY.F), Algeta's Prostate Cancer Drug


8/23/2011 8:07:55 AM

Germany's Bayer AG (BAYN.XE) and Norwegian partner Algeta ASA (ALSETA.OS) Tuesday said that U.S. drug regulators designated their experimental therapy Alpharadin for fast track approval, reinforcing views the prostate cancer medicine might have the potential for sales of over $1 billion. The U.S. Food and Drug Administration's decision to fast track Alpharadin follows recent clinical trial data showing it improved overall survival in patients with castration-resistant prostate cancer and symptomatic bone metastases. The trial was stopped early due to the impressive overall survival results.

Read at Market Watch
Read at Reuters
Read at Wall Street Journal
Read at Street Insider


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES